Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors

Abstract

Purpose

Treatment of late-stage prostate cancer by targeted radiotherapeutics such as ¹³¹I-MIP-1095 and ¹⁷⁷Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand therapy (RLT) with ¹⁷⁷Lu-PSMA-617 has not reached its full potential due to insufficient dose delivery to the tumor. We recently developed a dual-targeting radioiodinated ligand, RPS-027, that targets PSMA and uses albumin binding to enable good tumor uptake and significantly reduced kidney uptake in a preclinical model. Further development of this ligand is limited by the inability to independently modify PSMA and albumin binding and the requirement of I-131 for therapeutic application. We therefore sought to devise a new class of trifunctional ligands for RLT with (1) a high-affinity PSMA-binding domain, (2) an albumin-binding group (ABG), and (3) a chelator for radiometals such as ⁶⁸Ga³⁺, ¹⁷⁷Lu³⁺ and ²²⁵Ac³⁺.

Methods

Ligands incorporating a triazolylphenylurea-containing PSMA-targeting group, an N^ε-(2-(4-iodophenyl)acetyl)lysine ABG and the bifunctional chelator p-SCN-Bn-DOTA linked by a PEG-containing polymer containing 0,3,4,6,8 or 12 repeats were prepared. PSMA affinity was determined in LNCaP cells and uptake and tissue distribution was studied in mice bearing LNCaP tumor xenografts and compared to ¹⁷⁷Lu-PSMA-617. Imaging studies were performed up to 24 h post-injection (p.i.) using ⁶⁶Ga³⁺ and biodistribution studies at 4 h, 24 h and 96 h p.i. with ¹⁷⁷Lu³⁺.

Results

PSMA affinity was high (IC₅₀ = 1–10 nM) and inversely proportional to the linker length. Tumor uptake correlated with binding affinity and was significantly greater than for ¹⁷⁷Lu-PSMA-617 over 96 h. The highest uptake was achieved with ¹⁷⁷Lu-RPS-063 (30.0 ± 6.9 %ID/g; 4 h p.i.). Kidney uptake was generally high, with the exception of the lowest affinity ligand ¹⁷⁷Lu-RPS-067. Each of the compounds showed slower blood clearance than ¹⁷⁷Lu-PSMA-617, with clearance proportional to linker length.

Conclusions

The high tumor uptake achieved with these trifunctional ligands predicts larger (up to 4×) doses delivered to the tumor than can be achieved with ¹⁷⁷Lu-PSMA-617. Although PSMA-mediated kidney uptake was also observed, the exceptional area under the curve (AUC) in the tumor warrants further investigation of these novel ligands as candidates for RLT.

https://ift.tt/2wEAsjl